On June 27, 2025, Kura Oncology, Inc. entered into a co-promotion agreement with Kyowa Kirin to jointly market their product ziftomenib for treating leukemia in the U.S. This collaboration includes shared responsibilities and costs for promotion and medical affairs activities related to the drug.